Overview of Randomized Trials of Systemic Adjuvant Therapy
Part of the Cancer Treatment and Research book series (CTAR, volume 103)
The most influential analyses of the effectiveness of systemic adjuvant therapy of breast cancer are the 3 overview meta-analyses performed at Oxford and published in 19881, 19922, and 19983. These meta-analyses are a collaborative effort dependent on pooling of data by trialists of nearly all the randomized clinical trials of systemic adjuvant therapies. The major questions that were addressed by these Overview analyses were:
Is systemic adjuvant therapy of breast cancer effective?
Are there subsets of patients in whom given adjuvant therapies are particularly effective?
How effective is the current adjuvant therapy?
KeywordsEstrogen Receptor Endometrial Cancer Menopausal Status Node Positive Patient Adjuvant Tamoxifen
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 2.Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Early Breast Cancer Trialists’ Collaborative Group. Lancet 339:1–15, 71–85, 1992.Google Scholar
- 6.Fisher B, Dignam J, Bryant J, deCillis A, Wickerham DL, Wolmark N, et al. The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529–1542, 1996.PubMedCrossRefGoogle Scholar
- 8.Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Bowman D, Couture J, Dimitrov NV, Evans J, Farrar W, Kavanah M, Lickley HL, Margolese R, Paterson AHG, Robidoux A, Shibata H, Terz J. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14. J Natl Cancer Inst 86: 527–537, 1994.PubMedCrossRefGoogle Scholar
- 10.Henderson IC, Berry D, Demetri G. et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am. Soc. Clinical Oncology 17: 390a, 1998.Google Scholar
© Springer Science+Business Media New York 2000